title: Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
authors.affiliation: The University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Brent W
authors.initials: BW
authors.lastname: Weston
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Hayden
authors.forename: Kathryn G
authors.initials: KG
authors.lastname: Roberts
authors.forename: Susan
authors.initials: S
authors.lastname: Bowyer
authors.forename: Johann
authors.initials: J
authors.lastname: Hsu
authors.forename: George
authors.initials: G
authors.lastname: Fedoriw
authors.forename: Kathleen W
authors.initials: KW
authors.lastname: Rao
authors.forename: Charles G
authors.initials: CG
authors.lastname: Mullighan
mesh_terms: D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D015321:Gene Rearrangement; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics; D015534:Trans-Activators / Q000235:genetics
chemical_list: D001549:Benzamides; C081976:EBF1 protein, human; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D015534:Trans-Activators; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D020797:Receptor, Platelet-Derived Growth Factor beta